Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer

Dong Wook Kim, Nan Wu, Young Chul Kim, Pei Feng Cheng, Ryan Basom, Dongkyoon Kim, Colin T. Dunn, Anastasia Y. Lee, Keebeom Kim, Chang Sup Lee, Andrew Singh, Adi F. Gazdar, Chris R. Harris, Robert N. Eisenman, Kwon Sik Park, David MacPherson

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is a devastating neuroendocrine carcinoma. MYCL (L-Myc) is frequently amplified in human SCLC, but its roles in SCLC progression are poorly understood. We isolated preneoplastic neuroendocrine cells from a mouse model of SCLC and found that ectopic expression of L-Myc, c-Myc, or N-Myc conferred tumorforming capacity. We focused on L-Myc, which promoted pre-rRNA synthesis and transcriptional programs associated with ribosomal biogenesis. Deletion of Mycl in two genetically engineered models of SCLC resulted in strong suppression of SCLC. The high degree of suppression suggested that L-Myc may constitute a therapeutic target for a broad subset of SCLC. We then used an RNA polymerase I inhibitor to target rRNA synthesis in an autochthonous Rb/p53-deleted mouse SCLC model and found significant tumor inhibition. These data reveal that activation of RNA polymerase I by L-Myc and other MYC family proteins provides an axis of vulnerability for this recalcitrant cancer.

Original languageEnglish (US)
Pages (from-to)1289-1299
Number of pages11
JournalGenes and Development
Volume30
Issue number11
DOIs
StatePublished - Jun 1 2016

Fingerprint

Small Cell Lung Carcinoma
RNA Polymerase I
Neuroendocrine Carcinoma
Neuroendocrine Cells
immune RNA
RNA Precursors
Neoplasms

Keywords

  • Neuroendocrine
  • Oncogene
  • Progression
  • Ribosome biogenesis
  • Transcription factor

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Kim, D. W., Wu, N., Kim, Y. C., Cheng, P. F., Basom, R., Kim, D., ... MacPherson, D. (2016). Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. Genes and Development, 30(11), 1289-1299. https://doi.org/10.1101/gad.279307.116

Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. / Kim, Dong Wook; Wu, Nan; Kim, Young Chul; Cheng, Pei Feng; Basom, Ryan; Kim, Dongkyoon; Dunn, Colin T.; Lee, Anastasia Y.; Kim, Keebeom; Lee, Chang Sup; Singh, Andrew; Gazdar, Adi F.; Harris, Chris R.; Eisenman, Robert N.; Park, Kwon Sik; MacPherson, David.

In: Genes and Development, Vol. 30, No. 11, 01.06.2016, p. 1289-1299.

Research output: Contribution to journalArticle

Kim, DW, Wu, N, Kim, YC, Cheng, PF, Basom, R, Kim, D, Dunn, CT, Lee, AY, Kim, K, Lee, CS, Singh, A, Gazdar, AF, Harris, CR, Eisenman, RN, Park, KS & MacPherson, D 2016, 'Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer', Genes and Development, vol. 30, no. 11, pp. 1289-1299. https://doi.org/10.1101/gad.279307.116
Kim, Dong Wook ; Wu, Nan ; Kim, Young Chul ; Cheng, Pei Feng ; Basom, Ryan ; Kim, Dongkyoon ; Dunn, Colin T. ; Lee, Anastasia Y. ; Kim, Keebeom ; Lee, Chang Sup ; Singh, Andrew ; Gazdar, Adi F. ; Harris, Chris R. ; Eisenman, Robert N. ; Park, Kwon Sik ; MacPherson, David. / Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. In: Genes and Development. 2016 ; Vol. 30, No. 11. pp. 1289-1299.
@article{3f3fbc93fa4b4ba98f9e7825a6963d10,
title = "Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) is a devastating neuroendocrine carcinoma. MYCL (L-Myc) is frequently amplified in human SCLC, but its roles in SCLC progression are poorly understood. We isolated preneoplastic neuroendocrine cells from a mouse model of SCLC and found that ectopic expression of L-Myc, c-Myc, or N-Myc conferred tumorforming capacity. We focused on L-Myc, which promoted pre-rRNA synthesis and transcriptional programs associated with ribosomal biogenesis. Deletion of Mycl in two genetically engineered models of SCLC resulted in strong suppression of SCLC. The high degree of suppression suggested that L-Myc may constitute a therapeutic target for a broad subset of SCLC. We then used an RNA polymerase I inhibitor to target rRNA synthesis in an autochthonous Rb/p53-deleted mouse SCLC model and found significant tumor inhibition. These data reveal that activation of RNA polymerase I by L-Myc and other MYC family proteins provides an axis of vulnerability for this recalcitrant cancer.",
keywords = "Neuroendocrine, Oncogene, Progression, Ribosome biogenesis, Transcription factor",
author = "Kim, {Dong Wook} and Nan Wu and Kim, {Young Chul} and Cheng, {Pei Feng} and Ryan Basom and Dongkyoon Kim and Dunn, {Colin T.} and Lee, {Anastasia Y.} and Keebeom Kim and Lee, {Chang Sup} and Andrew Singh and Gazdar, {Adi F.} and Harris, {Chris R.} and Eisenman, {Robert N.} and Park, {Kwon Sik} and David MacPherson",
year = "2016",
month = "6",
day = "1",
doi = "10.1101/gad.279307.116",
language = "English (US)",
volume = "30",
pages = "1289--1299",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "11",

}

TY - JOUR

T1 - Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer

AU - Kim, Dong Wook

AU - Wu, Nan

AU - Kim, Young Chul

AU - Cheng, Pei Feng

AU - Basom, Ryan

AU - Kim, Dongkyoon

AU - Dunn, Colin T.

AU - Lee, Anastasia Y.

AU - Kim, Keebeom

AU - Lee, Chang Sup

AU - Singh, Andrew

AU - Gazdar, Adi F.

AU - Harris, Chris R.

AU - Eisenman, Robert N.

AU - Park, Kwon Sik

AU - MacPherson, David

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Small cell lung cancer (SCLC) is a devastating neuroendocrine carcinoma. MYCL (L-Myc) is frequently amplified in human SCLC, but its roles in SCLC progression are poorly understood. We isolated preneoplastic neuroendocrine cells from a mouse model of SCLC and found that ectopic expression of L-Myc, c-Myc, or N-Myc conferred tumorforming capacity. We focused on L-Myc, which promoted pre-rRNA synthesis and transcriptional programs associated with ribosomal biogenesis. Deletion of Mycl in two genetically engineered models of SCLC resulted in strong suppression of SCLC. The high degree of suppression suggested that L-Myc may constitute a therapeutic target for a broad subset of SCLC. We then used an RNA polymerase I inhibitor to target rRNA synthesis in an autochthonous Rb/p53-deleted mouse SCLC model and found significant tumor inhibition. These data reveal that activation of RNA polymerase I by L-Myc and other MYC family proteins provides an axis of vulnerability for this recalcitrant cancer.

AB - Small cell lung cancer (SCLC) is a devastating neuroendocrine carcinoma. MYCL (L-Myc) is frequently amplified in human SCLC, but its roles in SCLC progression are poorly understood. We isolated preneoplastic neuroendocrine cells from a mouse model of SCLC and found that ectopic expression of L-Myc, c-Myc, or N-Myc conferred tumorforming capacity. We focused on L-Myc, which promoted pre-rRNA synthesis and transcriptional programs associated with ribosomal biogenesis. Deletion of Mycl in two genetically engineered models of SCLC resulted in strong suppression of SCLC. The high degree of suppression suggested that L-Myc may constitute a therapeutic target for a broad subset of SCLC. We then used an RNA polymerase I inhibitor to target rRNA synthesis in an autochthonous Rb/p53-deleted mouse SCLC model and found significant tumor inhibition. These data reveal that activation of RNA polymerase I by L-Myc and other MYC family proteins provides an axis of vulnerability for this recalcitrant cancer.

KW - Neuroendocrine

KW - Oncogene

KW - Progression

KW - Ribosome biogenesis

KW - Transcription factor

UR - http://www.scopus.com/inward/record.url?scp=84974605091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974605091&partnerID=8YFLogxK

U2 - 10.1101/gad.279307.116

DO - 10.1101/gad.279307.116

M3 - Article

VL - 30

SP - 1289

EP - 1299

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 11

ER -